Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-014: MK-1084 ± cetuximab in KRAS G12C-mutant advanced solid tumors
2025-521737-91-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, open-label trial of calderasib in Sarcoma of the urogenital tract (2 arms), sponsored by Merck & Co. Primary endpoints: Objective Response Rate (ORR), Number of Participants Who Experience One or More Adverse Events (AEs) and 1 more. Planned start Nov 2025; status: authorised.
02
Drugs
calderasib
03
Conditions
Sarcoma of the urogenital tract
Beyond the preview
Go deeper on 2025-521737-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521737-91-00.